Merck KGaA to Relocate Its DeImmunisation Research From Scotland to U.S.
Merck KGaA announced that during the course of this year it will relocate its pharmaceutical research operations in Aberdeen, Scotland, to its larger biotech research facility in the United States. The Aberdeen site focuses on research to eliminate immunogenic properties from antibodies and other therapeutic proteins.
DeImmunisation(TM) technologies aimed at developing antibodies and other protein therapeutics with superior tolerability profiles will continue to be an important asset in the discovery and development of innovative biological drugs for Merck. In the future this activity will be performed exclusively at Merck's U.S. research center, EMD Lexigen, located in Billerica, near Boston, MA. An internal evaluation revealed that synergies can be expected from a full integration of these activities with the research for New Biologic Entities taking place at EMD Lexigen. In addition, contract DeImmunisation work for external customers will no longer be offered. Eighteen employees in Scotland will be affected by the consolidation and closure of the Aberdeen site.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous